Literature DB >> 21865386

Matrix protein-specific IgA antibody inhibits measles virus replication by intracellular neutralization.

Dihan Zhou1, Yan Zhang, Qiaoli Li, Yaoqing Chen, Benxia He, Jingyi Yang, Haobo Tu, Lei Lei, Huimin Yan.   

Abstract

Measles virus (MV) is still an imposing threat to public health. The matrix (M) protein has been shown not only to function as a structure block in the assembled MV virions, but also to regulate viral RNA synthesis, playing an important role in MV's replication and assembly. In the present study, we generated a panel of IgG monoclonal antibodies (MAbs) against M protein and successfully obtained one IgA MAb (5H7) from the IgG panel. Employing the polarized Vero cells grown in the two-chamber transwell model, we investigated whether M-specific 5H7 IgA MAb could suppress MV's replication and assembly. The data presented indicate that, while failing to show the activities of traditional neutralization and immune exclusion, M-specific IgA MAb was able to effectively inhibit viral replication by intracellular neutralization (78%), supporting the notion that the M protein is important for MV assembly and replication and implying that the M protein was an effective target antigen. The data also showed that MV had a long entry and assembly phase during viral replication, providing an extended window for IgA intervention. The colocalization of M proteins and M-specific 5H7 IgA MAbs demonstrated that the intracellular neutralization was due to the direct binding of the M-specific 5H7 IgA MAbs to the M proteins. In summary, the present study has added another example showing that IgA antibodies targeting internal viral antigens could proactively participate in mucosal immune protection by intracellular neutralization and has provided evidence that M protein might be included as a target antigen in future MV vaccine design.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21865386      PMCID: PMC3194966          DOI: 10.1128/JVI.00768-11

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  30 in total

1.  Measles in the United States during the postelimination era.

Authors:  Amy Parker Fiebelkorn; Susan B Redd; Kathleen Gallagher; Paul A Rota; Jennifer Rota; William Bellini; Jane Seward
Journal:  J Infect Dis       Date:  2010-10-07       Impact factor: 5.226

2.  Multiple functions of immunoglobulin A in mucosal defense against viruses: an in vitro measles virus model.

Authors:  Huimin Yan; Michael E Lamm; Ewa Björling; Yung T Huang
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

3.  Intracellular neutralization of virus by immunoglobulin A antibodies.

Authors:  M B Mazanec; C S Kaetzel; M E Lamm; D Fletcher; J G Nedrud
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-01       Impact factor: 11.205

4.  Absence of transmission of the D9 measles virus in the region of the Americas, November 2002 - May 2003.

Authors: 
Journal:  Epidemiol Bull       Date:  2003-03

Review 5.  Summary and conclusions: measles elimination meeting, 16-17 March 2000.

Authors:  Samuel L Katz; Alan R Hinman
Journal:  J Infect Dis       Date:  2004-05-01       Impact factor: 5.226

Review 6.  Measles: not just another viral exanthem.

Authors:  Trevor Duke; Charles S Mgone
Journal:  Lancet       Date:  2003-03-01       Impact factor: 79.321

7.  Measles virus matrix protein specifies apical virus release and glycoprotein sorting in epithelial cells.

Authors:  H Y Naim; E Ehler; M A Billeter
Journal:  EMBO J       Date:  2000-07-17       Impact factor: 11.598

8.  The matrix proteins of neurovirulent subacute sclerosing panencephalitis virus and its acute measles virus progenitor are functionally different.

Authors:  A Hirano; A H Wang; A F Gombart; T C Wong
Journal:  Proc Natl Acad Sci U S A       Date:  1992-09-15       Impact factor: 11.205

9.  Acute measles mortality in the United States, 1987-2002.

Authors:  Jacqueline Gindler; Sarah Tinker; Lauri Markowitz; William Atkinson; Loring Dales; Mark J Papania
Journal:  J Infect Dis       Date:  2004-05-01       Impact factor: 5.226

10.  Functional analysis of matrix proteins expressed from cloned genes of measles virus variants that cause subacute sclerosing panencephalitis reveals a common defect in nucleocapsid binding.

Authors:  A Hirano; M Ayata; A H Wang; T C Wong
Journal:  J Virol       Date:  1993-04       Impact factor: 5.103

View more
  15 in total

1.  EV71 infection correlates with viral IgG preexisting at pharyngo-laryngeal mucosa in children.

Authors:  Jingchang Xue; Yaoming Li; Xiaoyi Xu; Jie Yu; Hu Yan; Huimin Yan
Journal:  Virol Sin       Date:  2015-03-20       Impact factor: 4.327

2.  Mumps virus pathogenesis: Insights and knowledge gaps.

Authors:  Sigrid Gouma; Marion P G Koopmans; Rob S van Binnendijk
Journal:  Hum Vaccin Immunother       Date:  2016-07-25       Impact factor: 3.452

3.  Functions of Antibodies.

Authors:  Donald N Forthal
Journal:  Microbiol Spectr       Date:  2014-08-15

Review 4.  Beyond binding: antibody effector functions in infectious diseases.

Authors:  Lenette L Lu; Todd J Suscovich; Sarah M Fortune; Galit Alter
Journal:  Nat Rev Immunol       Date:  2017-10-24       Impact factor: 53.106

5.  Potential Role of Nonneutralizing IgA Antibodies in Cross-Protective Immunity against Influenza A Viruses of Multiple Hemagglutinin Subtypes.

Authors:  Kosuke Okuya; Reiko Yoshida; Rashid Manzoor; Shinji Saito; Tadaki Suzuki; Michihito Sasaki; Takeshi Saito; Yurie Kida; Akina Mori-Kajihara; Tatsunari Kondoh; Masahiro Sato; Masahiro Kajihara; Hiroko Miyamoto; Osamu Ichii; Hideaki Higashi; Ayato Takada
Journal:  J Virol       Date:  2020-06-01       Impact factor: 5.103

6.  Antibodies and their receptors: different potential roles in mucosal defense.

Authors:  Rachel E Horton; Gestur Vidarsson
Journal:  Front Immunol       Date:  2013-07-16       Impact factor: 7.561

7.  Intranasal delivery of influenza rNP adjuvanted with c-di-AMP induces strong humoral and cellular immune responses and provides protection against virus challenge.

Authors:  Maria Victoria Sanchez; Thomas Ebensen; Kai Schulze; Diego Cargnelutti; Paulina Blazejewska; Eduardo A Scodeller; Carlos A Guzmán
Journal:  PLoS One       Date:  2014-08-20       Impact factor: 3.240

8.  COVID-19 Outcomes in Patients Undergoing B Cell Depletion Therapy and Those with Humoral Immunodeficiency States: A Scoping Review.

Authors:  Jessica M Jones; Aiman J Faruqi; James K Sullivan; Cassandra Calabrese; Leonard H Calabrese
Journal:  Pathog Immun       Date:  2021-05-14

9.  Heterosubtypic antiviral activity of hemagglutinin-specific antibodies induced by intranasal immunization with inactivated influenza viruses in mice.

Authors:  Mieko Muramatsu; Reiko Yoshida; Hiroko Miyamoto; Daisuke Tomabechi; Masahiro Kajihara; Junki Maruyama; Takashi Kimura; Rashid Manzoor; Kimihito Ito; Ayato Takada
Journal:  PLoS One       Date:  2013-08-16       Impact factor: 3.240

10.  Comparison of antiviral activity between IgA and IgG specific to influenza virus hemagglutinin: increased potential of IgA for heterosubtypic immunity.

Authors:  Mieko Muramatsu; Reiko Yoshida; Ayaka Yokoyama; Hiroko Miyamoto; Masahiro Kajihara; Junki Maruyama; Naganori Nao; Rashid Manzoor; Ayato Takada
Journal:  PLoS One       Date:  2014-01-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.